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 We investigated the clinical significance of telomerase 
activity and telomere length in hepatocellular carcinomas 
(HCCs) and chronic liver diseases. Telomerase activity was 
assessed quantitatively using 'Stretch PCR' assay and telomere 
length by Southern blotting in 24 HCCs, 2 focal nodular 
hyperplasia, 8 liver cirrhosis, 10 chronic hepatitis and 8 
histologically normal livers. The latter were obtained from 
normal sections of resected specimens of cholangiocellular 
carcinoma, metastatic liver tumor or hemangioma. The rela-
tive titers of telomerase activity (RTA) were significantly 
higher in HCCs (average, 54 units) than in chronic liver 
diseases (average, 0.6 units) (P<0.001). In comparison, RTA was 
less than 2 units in non-malignant liver tissues. Telomere 
length in cirrhotic liver tissues was significantly shorter 
than in normal livers and tended to be shorter than those 
in chronic hepatitis. Telomere length and RTA correlated 
with the grading of tissue derangement in chronic liver 
diseases. Our results suggest that RTA estimated by Stretch 
PCR assay might be clinically useful for accurate diagnosis 
of liver diseases, particularly HCCs. In addition, telomere 
length seems to having a possibility as a useful predictor 
for risk of hepatocarcinogenesis. 
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Introduction
 The 10-15 kilobases of (TTAGGG) tandem repeats 
onto 3' ends of each chromosome are termed telomere 
repeats'. Telomere repeats cap both ends of the chro-
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mosome and protect them from attacks or fusion'. 
Human somatic cells lose telomere repeats in every 
cell division 3-5. Telomere repeats shorten during the 
cell cycle, and subsequent activation of the suppressor 
mechanism that arrests the cell cycle occurs'. On the 
other hand, certain enzymes such as telomerase coun-
teracts the shortening of telomere in immortalized cells'. 
Telomerase, a ribonucleoprotein, synthesizes telomere 
repeats and plays an important role in maintaining 
telomere length in several normal cells including germ 
cells and stem cells, or cancer cells8-'1. 
 Hepatocellular carcinoma (HCC) generally develops 
from hyperplastic hepatic nodules after chronic liver 
irritation including chronic hepatitis (CH) and/or liver 
cirrhosis (LC)12. In spite of recent developments in im-
aging diagnosis and histological examination with 
needle biopsy, it is often difficult to correctly diagnose 
small liver nodules, particularly well differentiated 
HCCs. Recently, attention has been paid to telomerase 
activity and telomere length as molecular events that 
assist in establishing the correct diagnosis and predict-
ing the progression of HCCs'3.'4. 
 Telomerase activity in human cancer cells has been 
successfully analyzed using qualitative or semiquantitative 
assay, known as telomeric repeat amplification proto-
col (TRAP)"-`. Although TRAP is a simple and sensi-
tive method, this semiquantitative analysis is neither 
always accurate nor able to differentiate HCCs from 
chronic liver diseases, because its PCR product de-
pends on the protein content of the cell extract with 
Taq polymerase inhibitor. On the other hand, in the 
Stretch PCR assay introduced by one of the authors 
(K. T)18 the telomerase product is purified and polymerase 
inhibitors are removed as much as possible before 
DNA amplification. Thus, this assay directly reflects 
telomerase activity and provides an accurate quantifi-
cation of telomerase activity. 
 Telomere length is important for chromosomal sta-
bility and regulation of cell cycle'. Chromosomes that
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have lost their telomeric DNA are highly recombinogenic. 
In this regard, the telomere length in certain types of 
cancer cells shortens with cell cycles. Furthermore, 
chromosomal changes often occur in cancer cells, a 
process also associated with telomere shorting". 
 In the present study, we quantitated telomerase ac-
tivity by Stretch PCR and telomere length by Southern 
blotting in HCCs, chronic liver diseases (LCs and CHs) 
and normal livers. In addition to comparing the above 
variables in the above tissue categories, we also exam-
ined the clinical significance of these measurements.
MATERIAL AND METHODS
Patients and tissue samples
 Informed consent from all patients and institutional 
review board approval for experimental use of sam-
ples were obtained. A total of 52 liver specimens in-
cluding 24 HCCs, 18 livers with chronic diseases (8 
LCs and 10 CHs), 2 focal nodular hyperplasias (FNH) 
and 8 normal livers were obtained from 35 patients 
who were treated surgically. Patients included 25 
males and 10 females, with a mean age of 63.0 years 
(range, 20 to 80 years). All 18 specimens of chronic 
liver diseases were obtained from non-tumorous liver 
parenchyma of the HCC patients. Normal liver speci-
mens were obtained from patients who underwent 
hepatectomy for other malignant diseases and benign 
liver tumors including metastatic liver tumors, 
cholangiocellular carcinomas and hemangiomas. 
Attention was paid to use the non-tumorous liver pa-
renchyma which was far from the tumor, and also to 
use the HCC specimen which was histological active 
in microscopic examination at the tumor margin. All 
samples were cryopreserved with dry ice immediately 
after resection and stored at -80° C until use.
Quantitative analysis of telomerase activity
 The Stretch PCR assay was performed according to 
the method previously described by Tatematsu et al. 18 
Briefly, approximately 50 mg of the tissue sample was 
minced in 3 ml of washing buffer (10 mM Hepes pH 
8.0, 1.5 MM MgCl2, 10 mM KC1 and 1 mM dithiothreitol) 
and homogenized in 900 ul of hypotonic buffer (10 
mM Hepes pH 8.0, 3 mM KCI, 1 mM dithiothreitol, 0.1 
mM PMSF, 1 mg/ml leupeptin, 2 mg/ml pepstatin A, 
0.5 % MEGA-9 and 10 U/ml RNasin) with subsequent 
incubation for 20 min on ice. The supernatant was 
collected and 2% volume of 5 M NaC1 was added. 
After incubation for 20 min at 4°C, the S-100 cell
extract was obtained following centrifugation at 
10,000 X g for 60 min at 4°C and 25% volume of glyc-
erol was added. Then, the S-100 extract was diluted 
with hypotonic buffer to a protein concentration of 
0.5 mg/ml. In the next step, 20 ul of the extract (10 
mg of protein content) was mixed with 2 X reaction 
mixture (100 mM Tris-potassium acetate; pH 8.5, 1 
mM dATP, 1 mM dTTP, 1 mM dGTP, 2 mM MgCl2, 2 
mM EGTA, 10 mM,8-mercaptoethanol, 0.1 mg/ml BSA, 2 
mM spermidine, 0.2 mM spermine and 20 pmol dena-
tured TAG-U [5'-GTAAAACGACGGCCAGTTTGGGGT-
TGGGGTTGGGGTTG-3']) and incubated for 60 min at 
30°C. The solution was added to proteinase K mix (10 
mM Tris HCI; pH 8.0, 0.1 % SDS, 10 mM EDTA and 
0.3 mg/ml proteinase K) and incubated for 15 min at 
37°C. After purification through phenol/chloroform ex-
traction and ethanol precipitation, DNA amplification 
was performed on the following conditions; 1) dilution 
with PCR buffer (20 mM Tris-HC1 pH 8.3, 75 mM KCI, 
1.5 mM MgCl2, 0.05 % W-1, and 5 pmol of CTA-R [ 5'-
CAGGAAACAGCTATGACCCCTAACCCTAACCCTTAA-
CCCT-3']), 2) add 10 ml of Taq mix [9 ml of PCR 
buffer, 0.2 ml of dNTP mix, 0.3 ml of Taq polymerase 
(EX Taq, Takara Co., Tokyo) and 0.5 ml of 3000 
Ci/mmol (a-32P) dCTP] which was prewarmed at 80°C, 
3) PCR was performed at the thermal cycle ; 93°C, 1 
min, 68°C, I min, 72°C, 2 min for 25 cycles, and fol-
lowed by 72°C, 10 min. After purification, the PCR 
products were analyzed by electrophoresis in 1 X Tris-
borate ethylenediami ne tetraacetic acid (EDTA) on de-
natured 7% polyacrylamide sequencing gel. Inactivation 
test was performed in which each S-100 protein was 
treated with 0.25 mg/ml of RNase A at 30°C for 30 
min before TAG-U was elongated by telomerase. The 
PCR products were measured by radioautography 30 
min after exposure to the imaging plate using BAS-
2000 (Fuji-Film Co., Tokyo). 
 Telomerase activity was quantitated by the ratio of 
total activity to that of 5 X 106 Hep G2 cells (human 
hepatoblastoma cell line) and was expressed as the 
relative titer of telomerase activity (RTA) [RTA (units) 
= A/B X 100] , where A is the total radioactivity of the 
sample, and B is the total radioactivity of 5 X 106 Hep 
G2 cells. Activity of < 10-2 units was considered nega-
tive. If the different RTA was obserbed within the 
same lesion in HCCs , the highest RTA was presented 
as the patient's data.
Analysis of telomere length
 Telomere length was measured as terminal restric-
tion fragment by Southern blotting. For this purpose, 
5 ,u g of isolated genomic DNA was digested for 4
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hours at 37°C with 15 U of Hinf I. After purification 
through phenol/chloroform extraction and ethanol 
precipitation, the digested DNA was loaded and blotted 
onto membranes, and was then probed with radiolabeled 
(TTAGGG)4. The DNA fragment length was calculated 
from the peak density of the hybridizing signal and 
compared to the molecular size marker.
Data processing and statistical analysis
 Correlations between telomerase activity/telomere 
length and clinicopathological features of HCCs, chroni-
cally diseased livers and normal livers were analyzed. 
Classification of pathological differentiation and the 
clinical stage of HCCs were based on the General Rules 
of Liver Cancer Study Group of Japan". The scoring 
of portal inflammation and grading of chronic liver 
disease were based on the Histological Activity Index 
(HAI) scoring system"'. The grading represented the 
total score of necrosis and inflammation. Differences 
in the percentages of tissues exhibiting telomerase ac-
tivity in each group were analyzed by the Fisher 
exact test. Differences in RTA, telomere length and 
age of patients were analyzed by the Mann-Whitney 
U test. A p value < 0.05 denoted the presence of a sta-
tistically significant difference.
Cell Numbers (log 10)
Figure 1. Relationship between telomerase activity measured 
in HepG2 cell extract and PCRa product. A good dose-response 
relationship was observed with extracts containing equivalents 
from 50 up to 5 X 106 HepG2b cells. PCR products are expressed 
in arbitrary units (r=0.98, P<0.01). 
Abbreviations; a. PCR, polymerase chain reaction; b.Hep G2, 
human hepatoblastoma cell line
RESULTS
Data processing and statistical analysis 
 We first evaluated quantitatively the accuracy of 
the Stretch PCR assay by the 10-fold serial dilution 
test using S-100 cell extract of 5 X 106 Hep G2 cells 
with and without pretermination by RNase. A close 
dose-dependent relationship was observed with ex-
tracts containing equivalents from 50 cells up to 5 X 
106 of Hep G2 cells. ( r=0.98, p<0.01, Figs. 1 and 2)
Telomerase activity in HCCs, chronically diseased livers 
and normal livers 
 Telomerase activity was noted in 23 of the 24 HCCs 
(96%) but only in 7 of 18 chronically diseased livers 
(38.9%). The percentage of tissues exhibiting telomerase 
activity was higher in HCCs than in chronically dis-
eased livers (p<0.01). In contrast, none of FNHs and 
normal liver tisues exhibit such activity. Further 
analysis showed that the RTA values of HCC samples 
were significantly higher (excluding a single negative 
case, range, 4.5 to 360 units, average, 54 units) than 
those of chronically diseased livers (excluding negative
Figure 2. Detection of PCRa products in HepG2b, HCCs`, LCs' 
and NLse by Stretch PCR . HCCs showed a strong telomerase 
activity (lane 1). LCs showed a weakly positive (lane 3) activ-
ity while no activity was noted in normal livers (lane 5). 
Each sample was pretreated with RNase (lanes 2, 4 and 6). 
lanes 7-11: S-100 samples of 5 X 106 cells of Hep G2 cell ex-
tracts, 1:10 dilution, 1:100 dilution, pretreatment with RNase 
and omission of S 100 sample as control, respectively. 
Abbreviations; a. PCR, polymerase chain reaction; b.Hep G2, 
human hepatoblastoma cell line; c. HCC, hepatocellular carci-
noma; d. LC, liver cirrhosis; d. NL, normal liver.
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cases, range, 0.02 to 1.7 units, average, 0.6 units) 
(p<0.001, Fig. 3). In livers with chronic diseases, only, 
one of 9 (11%) showed telomerase activity in cases 
with no or mild portal inflammation whereas 6 of 9 
(67%) cases with severe portal inflammation exhibited 
telomerase activity. In addition, the values of RTA in 
cases with severe portal inflammation were signifi-
cantly higher than those with mild portal inflamma-
tion. (P<0.01, Fig. 4).
 We also examined the correlation between RTA and 
telomere length and various clinicopathological pa-
rameters, including histological subtype, tumor size 
and microscopic finding in HCCs. However, no signifi-
cant correlation was observed (Table 1).
Telomere length in HCCs, chronically diseased livers and 
normal livers 
 The telomere length in LCs, HCCs and CHs was sig-
Table 1. Relationship between RTAa, telomere length and 
various clinicopathological parameters in HCCsb.
HCC FNH LC CH NL
Figure 3. RTAa in HCCsb, LCs`, CHs' and NLs°. RTA in HCCs 
was significantly higher than in chronic liver diseases (p<0.001), 
but there were no significant differences between LCs and 
CHs. No activity was detected in FNHs` and normal livers. 
Abbreviations; a. RTA, relative titers of telomerase activity; 
b. HCC, hepatocellular carcinoma; c. LC, liver cirrhosis; d. CH, 
chronic hepatitis; e. NL, normal livers. f. FNH, focal nodular 
hyperplasia.
Variable n RTA (units) Telomere length (Kb)` 
-_- -- -------------------------------------------------------------..---.------------.------...------------- -------..---.-----------.......-.. 
Histological differentiation N.Sd. 
     well 3 26.2±26.1 8.20±1.73 
     moderately 17 67.0±94.8 6.54±1.64 
     poorly 3 14.5±9.81 7.37±3.32 
     combined 1 21.0 5.8 
Tumor size N.S. 
     ± 5 cm 18 65.3±92.3 6.86±1.60 
     > 5 cm 6 24.2±15.0 6.72±2.70 
Microscopic intrahepatic metastasis N.S. 
     positive 9 74.9±117.1 6.41±1.72 
     negative 15 46.5±53.0 7.08±1.96 
Microscopic portal involvement N.S. 
     positive 4 110.5±167.0 5.82±2.54 
     negative 20 44.2±55.4 7.02±1.72
Data present the mean±SD, except one negative RTA. 
a. RTA, relative titers of telomerase activity; b.HCC, hepatocellular carcinoma; 
c.Kb, kilobase; n, number of samples; d.N.S., not significant.
Table 2. Telomere length in HCCs', LCsb, CHs` and normal 
livers
Portal inflammation score
Figure 4. Differences in RTAa in chronic liver disease. Eighteen 
samples of chronic liver diseases from non-tumorous part of 
HCCb were analyzed. Note the positive correlation between 
portal inflammation and RTA (p<0.01). Mild: grade 0 or 1 of 
portal inflammation, severe: grade 3 or 4. (/) LC` patient. (•) 
CH' patient. 
Abbreviations; a. RTA, relative titers of telomerase activity; 
b. HCC, hepatocellular carcinoma; c. LC, liver cirrhosis; d. CH 
chronic hepatitis.
Tissues n Telomere length (Kb)' Age 
------------------- -------------------- --- _ ..-- .................................... ....-----------------------.......-. 
HCC 24 6.94±1.89° 63.0±11.8 
LC 8 6.23±1.25` 66.0±6.09 
CH 10 7.50±1.64` 63.2±7.70 
Normal liver 8 9.49±2.02 60.8±10.2
Data represent the mean±SD. Age was not significantly different in the four 
groups. 
Abbreviations;a. HCC, hepatocellular carcinoma; b. LC, liver cirrhosis; c. CH. 
chronic hepatitis; d.Kb, kilobase; e. p<0.005 vs. normal livers; f.p<0.05 vs. normal 
livers.
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nificantly shorter than in normal livers (p<0.005, 
p<0.005 and p<0.05, respectively). Patient's age did not 
significantly influence teleomere length in all four tis-
sue groups (Table 2). A close correlation was observed 
between telomere length and grading of chronic liver 
disease (r=-0.49, p<0.05, Fig. 5).
Figure 5. Relationship between telomere length and grading 
scores in chronic liver diseases. Telomere length of 18 liver 
samples of chronic liver diseases from non-tumorous part of 
HCCa was analyzed. The grading score represented the total 
score of necrosis and inflammation in HAIb scoring system. 
Telomere length correlated with the grading score in HAI 
(r=-0.49, p<0.01). (•) LCc patient. (•) CHd patient. 
Abbreviations; a. HCC, hepatocellular carcinoma; b. HAI, his-
tology activity index; c. LC, liver cirrhosis; d. CH, chronic 
hepatitis.
DISCUSSION
 Several studies have examined telomerase activity, 
using TRAP assay, and telomere length in various liver 
diseases"-'". However, in these studies the activity was 
unexpectedly detected even in non-malignant tissues, 
especially chronic hepatitis. Furthermore, it was diffi-
cult to accurately distinguish between chronic and/or 
premalignant lesions from HCCs. Thus, more sensitive 
assays are necessary to accurately differentiate be-
tween liver tumors and benign chronic diseases or to 
predict cancerous lesions in chronic liver diseases"'. 
 In the present study, telomerase activity was de-
tected in most HCC specimens (95%). Such frequency 
was higher than those reported in other studies using 
TRAP assay (80-85%)']2324. Unexpectedly, a single case of 
HCC showed no telomerase activity. One possible reason 
for this finding is that several cancer cells may keep 
their telomere length without telomerase activity22. 
However, we can not rule out a possible degradation 
of essential telomerase template RNA during sampling
and/or storage. In non-malignant liver lesions, neither 
FNHs nor normal livers showed any activity, whereas 
7 of 18 cases (38.9%) with CHs and LCs showed a weak 
activity. Thus, the percentage of tissues showing 
telomerase activity does not seem to be a good parameter 
to differentiate these chronic liver diseases from HCCs. 
These results were consistent with the previous re-
ports using TRAP assay"•23.24. In contrast, no case of 
chronic liver disease with more than 2 units of RTA 
was observed in our study, indicating that it might be 
possible to differentiate these suspicious lesions from 
HCCs by quantification of RTA in the Stretch PCR 
assay. Another advantage of this assay is that it re-
quires only a small volume of tissue sample which 
can usually be obtained by needle biopsy 13 . Thus, the 
Stretch PCR assay might enhance the diagnosis of 
liver lesions. 
 There are several explanations for the weak 
telomerase activity in some liver samples with chronic 
diseases. First, frequent damage and regeneration of 
hepatocytes occurs in chronic liver diseases associated 
with excessive division of hepatocytes, which is be-
yond the normal senescence checkpoints, subsequently 
causing the expression of telomerase activity25-27. Second, 
infiltrating lymphocytes might possibly be the source 
of this activity, since these cells are known to exhibity 
telomerase activity'°. In fact, the RTA values in our 
study correlated well with the extent of lymphocyte 
infiltration present in portal inflammation in HAI scor-
ing. 
 Our results showed no significant correlation between 
telomerase activity and various clinicopathological pa-
rameters in HCCs. Previous studies, however, have re-
ported a high telomerase activity in poorly differenti-
ated HCCs than well differentiated HCCs232". It is possible 
that differences in the sensitivity of the Stretch PCR 
and TRAP assay may explain the different results. 
 Telomere length in HCCs was not shorter than in 
LCs, though it was shorter than that of normal livers. 
These results suggest that telomere length in HCC cells 
is regulated or elongated to a certain level by telomerase, 
and this is subsequently followed by immortalization 
of HCC cells. Telomere length of LCs was shortest 
among non-cancerous liver diseases in the present 
study, and correlated with the grade of HAI score, 
which represented the extent of inflammation and tis-
sue necrosis in liver diseases. These results support 
the notion that senescence of hepatocytes occurs fol-
lowing tissue derangement and subsequent regenera-
tion, especially in chronic hepatitis induced by hepati-
tis C virus and that the incidence of HCC increases 
with the advancement of the stage of the disease23,28. 
Considered together, our results suggest that telomere
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length might be one of the parameter for predicting 
the risk of hepatocarcinogenesis in hepatic tissues. 
 In conclusion, we demonstrated in the present study 
clear differences in RTA and telomere length between 
HCCs, chronically diseased livers and normal livers. A 
significantly higher percentage of HCC tissues exhib-
ited RTA than in non-cancerous liver tissues, even in 
tissues exhibiting telomerase activity. We also showed 
the possibility that telomere length might be a novel 
predictor of hepatocarcinogenesis in chronically dis-
eased liver.
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